RESUMO
Purpose: Recent studies have shown that the retinal pigment epithelium (RPE) relies on fatty acid oxidation (FAO) for energy, however, its role in overall retinal health is unknown. The only FAO disorder that presents with chorioretinopathy is long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD). Studying the molecular mechanisms can lead to new treatments for patients and elucidate the role of FAO in the RPE. This paper characterizes the chorioretinopathy progression in a recently reported LCHADD mouse model. Methods: Visual assessments, such as optokinetic tracking and fundus imaging, were performed in wildtype (WT) and LCHADD mice at 3, 6, 10, and 12 months of age. Retinal morphology was analyzed in 12-month retinal cross-sections using hematoxylin and eosin (H&E), RPE65, CD68, and TUNEL staining, whereas RPE structure was assessed using transmission electron microscopy (TEM). Acylcarnitine profiles were measured in isolated RPE/sclera samples to determine if FAO was blocked. Bulk RNA-sequencing of 12 month old male WT mice and LCHADD RPE/sclera samples assessed gene expression changes. Results: LCHADD RPE/sclera samples had a 5- to 7-fold increase in long-chain hydroxyacylcarnitines compared to WT, suggesting an impaired LCHAD step in long-chain FAO. LCHADD mice have progressively decreased visual performance and increased RPE degeneration starting at 6 months. LCHADD RPE have an altered structure and a two-fold increase in macrophages in the subretinal space. Finally, LCHADD RPE/sclera have differentially expressed genes compared to WT, including downregulation of genes important for RPE function and angiogenesis. Conclusions: Overall, this LCHADD mouse model recapitulates early-stage chorioretinopathy seen in patients with LCHADD and is a useful model for studying LCHADD chorioretinopathy.
Assuntos
Modelos Animais de Doenças , Epitélio Pigmentado da Retina , Animais , Camundongos , Epitélio Pigmentado da Retina/metabolismo , Epitélio Pigmentado da Retina/patologia , Camundongos Endogâmicos C57BL , 3-Hidroxiacil-CoA Desidrogenase de Cadeia Longa/metabolismo , Doenças da Coroide/genética , Doenças da Coroide/metabolismo , Masculino , Doenças Retinianas/genética , Doenças Retinianas/metabolismo , Doenças Retinianas/fisiopatologia , Microscopia Eletrônica de TransmissãoRESUMO
PURPOSE: Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency (LCHADD) is a rare fatty acid oxidation disorder characterized by recurrent episodes of metabolic decompensation and rhabdomyolysis, as well as retinopathy, peripheral neuropathy, and cardiac involvement, such as infantile dilated cardiomyopathy. Because LCHADD patients are surviving longer, we sought to characterize LCHADD-associated major cardiac involvement in adolescence and young adulthood. METHODS: A retrospective cohort of 16 adolescent and young adult participants with LCHADD was reviewed for cardiac phenotype. RESULTS: Major cardiac involvement occurred in 9 of 16 participants, including sudden death, out-of-hospital cardiac arrest, acute cardiac decompensations with heart failure and/or in-hospital cardiac arrest, end-stage dilated cardiomyopathy, and moderate restrictive cardiomyopathy. Sudden cardiac arrest was more common in males and those with a history of infant cardiomyopathy. CONCLUSION: The cardiac manifestations of LCHADD in adolescence and early adulthood are complex and distinct from the phenotype seen in infancy. Life-threatening arrhythmia occurs at substantial rates in LCHADD, often in the absence of metabolic decompensation or rhabdomyolysis. The potential risk factors identified here-male sex and history of infant cardiomyopathy-may hint at strategies for risk stratification and possibly the prevention of these events.
Assuntos
Erros Inatos do Metabolismo Lipídico , Fenótipo , Humanos , Masculino , Adolescente , Feminino , Adulto Jovem , Adulto , Erros Inatos do Metabolismo Lipídico/genética , Erros Inatos do Metabolismo Lipídico/patologia , Estudos Retrospectivos , Rabdomiólise/genética , Rabdomiólise/patologia , Rabdomiólise/enzimologia , 3-Hidroxiacil-CoA Desidrogenase de Cadeia Longa/genética , Cardiomiopatia Dilatada/genética , Cardiomiopatia Dilatada/patologia , Cardiomiopatias/genética , Cardiomiopatias/patologia , Morte Súbita Cardíaca/etiologia , Morte Súbita Cardíaca/patologiaRESUMO
Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) is a fatty acid oxidation disorder (FAOD) caused by a pathogenic variant, c.1528 G > C, in HADHA encoding the alpha subunit of trifunctional protein (TFPα). Individuals with LCHADD develop chorioretinopathy and peripheral neuropathy not observed in other FAODs in addition to the more ubiquitous symptoms of hypoketotic hypoglycemia, rhabdomyolysis and cardiomyopathy. We report a CRISPR/Cas9 generated knock-in murine model of G1528C in Hadha that recapitulates aspects of the human LCHADD phenotype. Homozygous pups are less numerous than expected from Mendelian probability, but survivors exhibit similar viability with wildtype (WT) littermates. Tissues of LCHADD homozygotes express TFPα protein, but LCHADD mice oxidize less fat and accumulate plasma 3-hydroxyacylcarnitines compared to WT mice. LCHADD mice exhibit lower ketones with fasting, exhaust earlier during treadmill exercise and develop a dilated cardiomyopathy compared to WT mice. In addition, LCHADD mice exhibit decreased visual performance, decreased cone function, and disruption of retinal pigment epithelium. Neurological function is affected, with impaired motor function during wire hang test and reduced open field activity. The G1528C knock-in mouse exhibits a phenotype similar to that observed in human patients; this model will be useful to explore pathophysiology and treatments for LCHADD in the future.
Assuntos
Cardiomiopatias , Erros Inatos do Metabolismo Lipídico , Rabdomiólise , Humanos , Animais , Camundongos , Modelos Animais de Doenças , Cardiomiopatias/genética , Erros Inatos do Metabolismo Lipídico/genética , Rabdomiólise/genética , Subunidade alfa da Proteína Mitocondrial TrifuncionalRESUMO
BACKGROUND: The plasma acylcarnitine profile is frequently used as a biochemical assessment for follow-up in diagnosed patients with fatty acid oxidation disorders (FAODs). Disease specific acylcarnitine species are elevated during metabolic decompensation but there is clinical and biochemical heterogeneity among patients and limited data on the utility of an acylcarnitine profile for routine clinical monitoring. METHODS: We evaluated plasma acylcarnitine profiles from 30 diagnosed patients with long-chain FAODs (carnitine palmitoyltransferase-2 (CPT2), very long-chain acyl-CoA dehydrogenase (VLCAD), and long-chain 3-hydroxy acyl-CoA dehydrogenase or mitochondrial trifunctional protein (LCHAD/TFP) deficiencies) collected after an overnight fast, after feeding a controlled low-fat diet, and before and after moderate exercise. Our purpose was to describe the variability in this biomarker and how various physiologic states effect the acylcarnitine concentrations in circulation. RESULTS: Disease specific acylcarnitine species were higher after an overnight fast and decreased by approximately 60% two hours after a controlled breakfast meal. Moderate-intensity exercise increased the acylcarnitine species but it varied by diagnosis. When analyzed for a genotype/phenotype correlation, the presence of the common LCHADD mutation (c.1528G > C) was associated with higher levels of 3-hydroxyacylcarnitines than in patients with other mutations. CONCLUSIONS: We found that feeding consistently suppressed and that moderate intensity exercise increased disease specific acylcarnitine species, but the response to exercise was highly variable across subjects and diagnoses. The clinical utility of routine plasma acylcarnitine analysis for outpatient treatment monitoring remains questionable; however, if acylcarnitine profiles are measured in the clinical setting, standardized procedures are required for sample collection to be of value.
Assuntos
Cardiomiopatias/sangue , Carnitina O-Palmitoiltransferase/deficiência , Carnitina/análogos & derivados , Síndrome Congênita de Insuficiência da Medula Óssea/sangue , Erros Inatos do Metabolismo Lipídico/sangue , Erros Inatos do Metabolismo/sangue , Doenças Mitocondriais/sangue , Miopatias Mitocondriais/sangue , Proteína Mitocondrial Trifuncional/deficiência , Doenças Musculares/sangue , Doenças do Sistema Nervoso/sangue , Rabdomiólise/sangue , 3-Hidroxiacil-CoA Desidrogenases/genética , 3-Hidroxiacil-CoA Desidrogenases/metabolismo , Acetil-CoA C-Aciltransferase/genética , Acetil-CoA C-Aciltransferase/metabolismo , Acil-CoA Desidrogenase de Cadeia Longa/sangue , Isomerases de Ligação Dupla Carbono-Carbono/genética , Isomerases de Ligação Dupla Carbono-Carbono/metabolismo , Cardiomiopatias/dietoterapia , Cardiomiopatias/patologia , Cardiomiopatias/terapia , Carnitina/sangue , Carnitina/genética , Carnitina/metabolismo , Carnitina O-Palmitoiltransferase/sangue , Síndrome Congênita de Insuficiência da Medula Óssea/dietoterapia , Síndrome Congênita de Insuficiência da Medula Óssea/patologia , Síndrome Congênita de Insuficiência da Medula Óssea/terapia , Enoil-CoA Hidratase/genética , Enoil-CoA Hidratase/metabolismo , Terapia por Exercício , Jejum , Feminino , Humanos , Erros Inatos do Metabolismo Lipídico/dietoterapia , Erros Inatos do Metabolismo Lipídico/patologia , Erros Inatos do Metabolismo Lipídico/terapia , 3-Hidroxiacil-CoA Desidrogenase de Cadeia Longa/sangue , Masculino , Erros Inatos do Metabolismo/dietoterapia , Erros Inatos do Metabolismo/patologia , Erros Inatos do Metabolismo/terapia , Doenças Mitocondriais/dietoterapia , Doenças Mitocondriais/patologia , Doenças Mitocondriais/terapia , Miopatias Mitocondriais/dietoterapia , Miopatias Mitocondriais/patologia , Miopatias Mitocondriais/terapia , Proteína Mitocondrial Trifuncional/sangue , Doenças Musculares/dietoterapia , Doenças Musculares/patologia , Doenças Musculares/terapia , Doenças do Sistema Nervoso/dietoterapia , Doenças do Sistema Nervoso/patologia , Doenças do Sistema Nervoso/terapia , Racemases e Epimerases/genética , Racemases e Epimerases/metabolismo , Rabdomiólise/dietoterapia , Rabdomiólise/patologia , Rabdomiólise/terapiaRESUMO
BACKGROUND: Phenylketonuria (PKU) treatment consists of life-long protein restriction and Phe-free medical foods for adequate nutritional intake and growth. A relationship between body composition and blood phenylalanine (Phe) concentrations in subjects with PKU has been proposed but this has not been consistently reported. METHODS: Dietary intake, lean body mass (LBM) and fat mass (FM) were measured in 30 pediatric subjects with PKU compared to 30 age, and sex matched controls. The relationship between body composition and blood Phe was analyzed within the PKU cohort from clinically collected dried blood spot Phe concentrations. RESULTS: Male subjects with PKU had less LBM% and more FM% than controls (p = .024). There was no difference in LBM% and FM% among female subjects. Age (p = .02) and FM% (p = .02) were positively correlated to dried blood spot Phe. Synthetic protein intake (g/kg body weight) was negatively correlated with dried blood spot Phe (p = .04). Natural protein intake was not related to blood spot Phe. CONCLUSIONS: Children with PKU face additional dietary challenges maintaining healthy growth and body composition while keeping Phe levels low. We observed higher FM% and lower LBM% in male subjects with PKU. Correlations do not prove cause and effect but suggest a relationship between increased blood Phe, lower synthetic protein intake and increased FM%. Future studies may explore if lower blood Phe concentrations is associated with a lower FM% and higher LBM%; particularly among adult patients now managed on pegvaliase (Palynziq®) who consume normal amounts of natural protein or among younger patients who consume glycomacropeptide (GMP).
RESUMO
Medical nutrition therapy for long-chain fatty acid oxidation disorders (LC-FAODs) currently emphasizes fasting avoidance, restricted dietary long-chain fatty acid intake, supplementation with medium chain triglycerides, and increased carbohydrate intake. We hypothesize that increasing dietary protein intake relative to carbohydrate intake would preserve metabolic control yet induce physical benefits including reduced hepatic lipogenesis. Therefore, we compared two dietary approaches with similar fat intake but different carbohydrate to protein ratios in participants diagnosed with LC-FAODs. Thirteen participants were enrolled and randomized into either a high-protein (PRO) or a high-carbohydrate (CHO) diet for 4 months. Baseline and 4-month assessments included body composition, ectopic lipid deposition, and resting energy expenditure. End of study assessments also included total energy expenditure, metabolic responses to oral feedings, and whole-body fatty acid oxidation capacity. At the end of the dietary intervention, both groups had similar energy expenditure, fat and glucose oxidation rates, and glucolipid responses to mixed meal and oral glucose loads. Neither dietary group experienced worsening symptoms related to their LC-FAOD. Compared to the CHO group, the PRO group exhibited increased blood levels of short-chain acylcarnitines, reduced intrahepatic lipid content, and maintained lean body mass while the CHO group lost lean mass. In patients with LC-FAODs, increasing protein intake maintained metabolic control, reduced liver fat without risk of metabolic decompensation, and helped preserve lean body mass. We propose that a modest increase in dietary protein along with fasting avoidance and fat restriction may improve body composition and energy expenditure in patients with LC-FAODs.
Assuntos
Proteínas Alimentares/administração & dosagem , Ácidos Graxos/metabolismo , Erros Inatos do Metabolismo Lipídico/dietoterapia , Triglicerídeos/uso terapêutico , Adolescente , Adulto , Composição Corporal , Criança , Carboidratos da Dieta/administração & dosagem , Metabolismo Energético , Feminino , Glucose/metabolismo , Humanos , Metabolismo dos Lipídeos , Erros Inatos do Metabolismo Lipídico/metabolismo , Fígado/metabolismo , Masculino , Oxirredução , Adulto JovemRESUMO
The purpose of the following paper is to present a project developed within the framework of collaboration between two foundations, Fundación Kaleidos (Argentina) and Children Action (Switzerland). The aim of this project is to developed diverse programs to support and empower adolescent mothers and fathers as well as their children. Adolescents whose rights are very often not respected and who find themselves alone having to confront the negative prejudices of the adults around them regarding the parenthood, which they now face. The objectives of the programs are as follows: the promotion of the well-being of the adolescents and the development of a personal project around education or work, the promotion of early child development of their infants, to address the problems around gender inequality and the promotion of an intersectional network between distinct sectors of society (public, private and NGO). By means of an integral program, we aim to tackle the diverse aspects of the lives of the adolescents in question and their children. Their rights and their environment are key to developing the maximum potential of each individual and their families.
Assuntos
Pais , Adolescente , Argentina , Feminino , Humanos , Masculino , Ajustamento SocialRESUMO
The purpose of the following paper is to present a project developed within the framework of collaboration between two foundations, Fundación Kaleidos (Argentina) and Children Action (Switzerland). The aim of this project is to developed diverse programs to support and empower adolescent mothers and fathers as well as their children. Adolescents whose rights are very often not respected and who find themselves alone having to confront the negative prejudices of the adults around them regarding the parenthood, which they now face. The objectives of the programs are as follows: the promotion of the well-being of the adolescents and the development of a personal project around education or work, the promotion of early child development of their infants, to address the problems around gender inequality and the promotion of an intersectional network between distinct sectors of society (public, private and NGO). By means of an integral program, we aim to tackle the diverse aspects of the lives of the adolescents in question and their children. Their rights and their environment are key to developing the maximum potential of each individual and their families.
Assuntos
Pais , Adolescente , Ajustamento Social , Argentina , Feminino , Humanos , MasculinoRESUMO
The 'foetal carbamazepine syndrome' is characterised by facial dysmorphism associated to cardiovascular, nervous system, urinary tract and skeletal anomalies. The authors present the case of a neonate born to a 33-year-old epileptic woman treated with long term carbamazepine (CMZ) therapy. Four of her pregnancies exposed to the drug showed bad outcomes. The actual pregnancy ended by caesarean section, a female was born showing facial dysmorphism, hypoplasic nails, xyphosis and myelomeningocele. After 7 days of birth, the infant developed severe neutropenia, moderate pulmonary hypertension, multiple organ failure and died. The karyotype was 46, XX. This case represents an example of the wide spectrum of the syndrome and contributes to describe the clinical profile of the 'foetal carbamazepine syndrome'. The delineation of the foetal carbamazepine syndrome's phenotype remains incomplete, since many of the clinical manifestations are shared with the effect of others anticonvulsants, therefore further studies are needed to determine the specific noxious effects of CMZ in utero.
Assuntos
Anormalidades Induzidas por Medicamentos/etiologia , Anticonvulsivantes/efeitos adversos , Carbamazepina/efeitos adversos , Adulto , Anticonvulsivantes/uso terapêutico , Carbamazepina/uso terapêutico , Epilepsia/tratamento farmacológico , Feminino , Humanos , Recém-Nascido , Fenótipo , Gravidez , Complicações na Gravidez/tratamento farmacológico , Índice de Gravidade de DoençaRESUMO
Lef-1 and PITX2 function in the Wnt signaling pathway by recruiting and interacting with beta-catenin to activate target genes. Chromatin immunoprecipitation (ChIP) assays identified the Lef-1 promoter as a PITX2 downstream target. Transgenic mice expressing LacZ driven by the 2.5-kb LEF-1 promoter demonstrated expression in the tooth epithelium correlated with endogenous Lef-1 FL epithelial expression. PITX2 isoforms regulate the LEF-1 promoter, and beta-catenin synergistically enhanced activation of the LEF-1 promoter in combination with PITX2 and Lef-1 isoforms. PITX2 enhances endogenous expression of the full-length beta-catenin-dependent Lef-1 isoform (Lef-1 FL) while decreasing expression of the N-terminally truncated beta-catenin-independent isoform. Our research revealed a novel interaction between PITX2, Lef-1, and beta-catenin in which the Lef-1 beta-catenin binding domain is dispensable for its interaction with PITX2. PITX2 interacts with two sites within the Lef-1 protein. Furthermore, beta-catenin interacts with the PITX2 homeodomain and Lef-1 interacts with the PITX2 C-terminal tail. Lef-1 and beta-catenin interact simultaneously and independently with PITX2 through two different sites to regulate PITX2 transcriptional activity. These data support a role for PITX2 in cell proliferation, migration, and cell division through differential Lef-1 isoform expression and interactions with Lef-1 and beta-catenin.